Peptide Injection Sites: Where They Go and How to Rotate
The FDA labels for Ozempic, Wegovy, and Zepbound name three subcutaneous injection sites, the abdomen, the thigh, and the upper arm, and each tells you to rotate the site. Research peptides have no FDA label, so there is no approved site list for them. Follow your prescriber and the product label.[1]
Where do you inject peptides subcutaneously?
For the three GLP-1 medicines whose labels we checked, the answer is the same. The Ozempic label says to inject subcutaneously in the abdomen, thigh, or upper arm, and the Wegovy label gives the same three sites.[1][2] The Zepbound label names the abdomen and the thigh, and says another person should give an injection in the back of the upper arm.[3] Site lists belong to a product, not to peptides in general. Egrifta WR, an FDA-approved peptide made of tesamorelin, is labeled for the abdomen only.[4] Peptides sold for research have no FDA label at all, so no approved site or technique exists for them.[8] Subcutaneous means into the fatty layer just under the skin, not into muscle or a vein, and the Zepbound label says not to inject into a muscle or a vein.[3] Your prescriber or pharmacist can show you the right site for your product.
| Site | Ozempic | Wegovy | Zepbound | Self-inject? |
|---|---|---|---|---|
| Abdomen | Named | Named | Named | Yes |
| Thigh | Named | Named | Named | Yes |
| Upper arm | Named | Named | Back of upper arm, given by another person | Zepbound: no |
| Any other site | Not named | Not named | Not named | Ask your prescriber |
Why do you need to rotate injection sites?
Every label we checked tells you to rotate. Ozempic says to change the injection site with each injection and not to use the same site every time, Wegovy says to rotate sites with each dose, and Zepbound says the same.[1][2][3] The medical reason comes from insulin research. The Forum for Injection Technique and Therapy recommendations, written by 183 diabetes experts and published in Mayo Clinic Proceedings in 2016, describe lipohypertrophy as a frequent complication that distorts insulin absorption. They advise that injections not be given into these lesions and that correct site rotation will help prevent them.[5] That evidence comes from people who inject insulin. Studies of the same problem in people who use research peptides are lacking, so applying it to other injectables is a precaution, not a proven finding in those users.
How often should you rotate injection sites?
Rotate at every injection. That is the instruction on all three labels, and none of them gives a distance between spots or a number of rest days before a site can be used again, so this page does not invent one.[1][2][3] The labels do clarify what counts as a new site. Zepbound says to change the site each week and that you may use the same area of your body if you choose a different spot in that area.[3] Ozempic allows an injection of Ozempic and insulin in the same body area, but not right next to each other, and never mixed in one injection.[1] In practice, rotating means you can work through the several spots in the abdomen, then the thigh, instead of returning to the spot you used last time. Keeping a written record is the simple way to know where the last injection went.
Which injection site absorbs best?
No source we found ranks the sites by absorption, so this page does not either. For the approved GLP-1 medicines, the labels allow any of their named sites. The Wegovy label says the time of day and the injection site can be changed without the need for a dosage modification.[2] That means a change of site is not a reason to change a dose, and it means you should not choose a site by a rumor about speed. Percent differences between sites that appear online have not been verified here, so they are left out. What the evidence does support is narrower. Injecting into a changed area of tissue can distort absorption, which the insulin recommendations describe, and that is one reason rotation is advised.[5] If a site seems to change how a medicine works for you, tell your prescriber instead of adjusting anything on your own.
What is lipohypertrophy and how common is it?
Lipohypertrophy is a lesion in the tissue at injection sites that forms with repeated injections in the same place. The insulin recommendations call it a frequent complication of therapy that distorts insulin absorption.[5] A systematic review and meta-analysis in the Journal of Diabetes Investigation pooled 26 studies with 12,493 participants and found a pooled prevalence of 38 percent among insulin-treated people, with a 95 percent confidence interval of 29 to 46 percent. Prevalence was higher in type 2 diabetes, at 49 percent, than in type 1, at 34 percent.[6] These numbers describe insulin injectors, not people who use GLP-1 medicines or research peptides, and the authors noted large differences between the studies. If a spot on your skin looks or feels different from the skin around it, tell a clinician and avoid injecting into it until it has been checked.
Where should you not inject?
Several limits come straight from labels. The Egrifta WR label says not to inject into scar tissue, bruises, or the navel.[4] The Zepbound label says not to inject into a muscle or a vein.[3] The Ozempic label says not to use the same site for each injection, to use a new needle for every injection, and never to share a pen, even if the needle has been changed.[1] Beyond the site, FDA guidance on sharps says used needles and syringes should go straight into a sharps disposal container, and that if you have no approved container, a heavy plastic household container such as a detergent bottle can serve.[7] If an injection leaves a hard area, lasting pain, or signs of infection, contact a clinician. Do not choose a site for a research peptide on the strength of an online chart. No FDA label names one.[8]
How do you keep track of injection site rotation?
Write down the site with every dose, then look back at the list before you inject. A paper note works. The point is to see your own pattern, with the date beside each site. In PepTrac for iPhone, you tap a zone on a front and back body map when you log a dose. The Application Sites screen then shows, for each week, each site's share of that week's logged doses, a count of doses with no site recorded, and a list of recent doses with labels such as 3 days ago. Heavy use of one spot stands out, which makes uneven rotation easy to catch. PepTrac is a logbook. It does not recommend your next site, and the map includes zones that no GLP-1 label names, so the choice of site stays with you and your prescriber.
| Label-named site | PepTrac map zones | Zones |
|---|---|---|
| Abdomen | Left and right upper, mid, and lower abdomen | 6 |
| Thigh | Left and right thigh, left and right lower thigh | 4 |
| Back of upper arm | Left and right triceps | 2 |
Frequently asked questions
Can I inject in the same spot every week?
The labels say no. Ozempic says to change the injection site with each injection, and Zepbound says to rotate each week and choose a different spot, even inside the same body area.
Does the injection site change how well semaglutide works?
The Wegovy label says the injection site can be changed without the need for a dosage modification. No source we found ranks the sites by how well they work, so none is claimed here.
Can I inject a GLP-1 and insulin in the same area?
The Ozempic label says you may inject it and insulin in the same body area, but not right next to each other. The two must be separate injections and are never mixed.
Is the upper arm okay to self-inject?
Ozempic and Wegovy list the upper arm. Zepbound says another person should give the injection in the back of the upper arm, so check the label for your own product.
Where do you inject BPC-157 or TB-500?
They are not FDA-approved and have no label, so there is no approved site or technique to report. The FDA lists safety concerns for compounded BPC-157. Ask a clinician instead of an online chart.
Does PepTrac choose my next injection site?
No. PepTrac records the site you pick on a body map and shows your history by week. It is a logbook and does not recommend a site, a dose, or a schedule.
Sources
- DailyMed, National Library of Medicine (Novo Nordisk). Ozempic (semaglutide) injection prescribing information. Accessed October 3, 2026.
- DailyMed, National Library of Medicine (Novo Nordisk). Wegovy (semaglutide) prescribing information. Accessed October 3, 2026.
- DailyMed, National Library of Medicine (Eli Lilly). Zepbound (tirzepatide) prescribing information. Accessed October 3, 2026.
- DailyMed, National Library of Medicine (Theratechnologies). Egrifta WR (tesamorelin) prescribing information. Accessed October 3, 2026.
- Mayo Clinic Proceedings (PubMed). Frid et al., New Insulin Delivery Recommendations (2016). Accessed October 3, 2026.
- Journal of Diabetes Investigation (PubMed). Deng et al., Prevalence of lipohypertrophy in insulin-treated diabetes patients: a systematic review and meta-analysis. Accessed October 3, 2026.
- U.S. Food and Drug Administration. Safely Using Sharps (Needles and Syringes) at Home, at Work and on Travel. Accessed October 3, 2026.
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Accessed October 3, 2026.
Written and maintained by the team that builds PepTrac. Every calculator on this site runs the same tested math as the app. Read how we research, cite, and update pages in our editorial policy.
